

Cite this: *RSC Chem. Biol.*, 2020,  
1, 209Received 16th April 2020,  
Accepted 24th July 2020

DOI: 10.1039/d0cb00048e

rsc.li/rsc-chembio

## Tranlycypromine specificity for monoamine oxidase is limited by promiscuous protein labelling and lysosomal trapping†

Jonas Drechsel,<sup>a</sup> Christina Kyrousi,<sup>b</sup> Silvia Cappello<sup>b</sup> and Stephan A. Sieber<sup>ib</sup>\*<sup>a</sup>

Monoamine oxidases MAOA and MAOB catalyze important cellular functions such as the deamination of neurotransmitters. Correspondingly, MAO inhibitors are used for the treatment of severe neuropsychiatric disorders such as depression. A commonly prescribed drug against refractory depression is tranlycypromine, however, the side effects are poorly understood. In order to decipher putative off-targets, we synthesized two tranlycypromine probes equipped with either an alkyne moiety or an alkyne-diazirine minimal photocrosslinker for *in situ* proteome profiling. Surprisingly, LC-MS/MS analysis revealed low enrichment of MAOA and relatively promiscuous labeling of proteins. Photoprobe labeling paired with fluorescent imaging studies revealed lysosomal trapping which could be largely reverted by the addition of lysosomotropic drugs.

Monoamine oxidases A and B (MAOA and MAOB) catalyze the deamination of neurotransmitters such as norepinephrine, serotonin and dopamine to the corresponding aldehydes which are further processed by *e.g.* aldehyde dehydrogenases (ALDHs) into the corresponding acids (Fig. 1A). The degradation of these molecules is important for neurotransmission and brain functions such as emotional behaviours.<sup>1,2</sup> Thus, inhibition of MAO enzymes has become a viable strategy to treat depression and other nervous system or neurological disorders such as Parkinson's disease.<sup>3-6</sup> MAO inhibitors (MAOI) were first introduced in the 1950s but due to side effects and safety concerns are only administered after treatment with other drugs fails. Some commonly reported side effects caused by MAOIs such as tranlycypromine include gastrointestinal disorder, headaches and fatigue.<sup>7</sup> Adverse effects are also experienced when MAOIs are administered in combination with primary amine-containing drugs.<sup>8</sup> The clearance of amine-containing molecules such as chloroquine relies on MAO deamination; consequently, co-administration with tranlycypromine must be avoided.<sup>9</sup> Despite these known

side effects, few proteomic studies on the target selectivity of MAOIs have been conducted. Probes based on the pargyline, rasagiline and selegiline scaffolds were investigated by gel-based proteomics as well as whole cell imaging, which confirmed binding to predominantly MAOA and MAOB.<sup>10-15</sup> These molecules work by reacting with the covalently bound cofactor FAD upon radical activation.<sup>16</sup> Despite these detailed mechanistic insights, a gel-free LC-MS/MS study for off-target profiling of major drugs such as tranlycypromine and pargyline is hitherto unreported. Herein, we synthesize tranlycypromine probes to elucidate the off-target profiles as well as their cellular localization in comparison to pargyline (Fig. 1B). The results indicate that unlike pargyline, tranlycypromine hits




Fig. 1 (A) General mechanism of the oxidative deamination of monoamines to the corresponding aldehydes by MAO, followed by further oxidation to carboxylic acids by ALDH. (B) Structures of marketed MAO inhibitors pargyline and tranlycypromine as well as their corresponding ABPP-probes used in this study.

<sup>a</sup> Department of Chemistry, Technical University of Munich, Lichtenbergstraße 4, 85748 Garching, Germany. E-mail: stephan.sieber@tum.de

<sup>b</sup> Max Planck Institute of Psychiatry, Kraepelinstraße 2, 80804 Munich, Germany

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0cb00048e



**Scheme 1** Synthesis of tranylcypromine-derived flavin binding probe (**FBP2**) and flavin binding photo-probe (**FBPP2**).

MAOA to a lesser degree in comparison to several off-targets including ALDHs. By incorporation of a photolabile reactive group, we additionally show major lysosomal trapping of tranylcypromine, which can be reduced by pre-treatment with lysosomotropic compounds like chloroquine.

First, we set out to directly decipher the specificity of tranylcypromine in living cells. For this, we designed two probe scaffolds, to account for both the irreversible and reversible binding partners of the compound (Fig. 1B). In the case of targeting irreversible binders such as flavin-dependent enzymes, we synthesized probe **FBP2** which exhibits a terminal alkyne linked *via* an ether to the benzene ring of tranylcypromine.<sup>17</sup> In brief, the synthesis was initiated by amine protection of (*trans*)-2-(4-hydroxyphenyl)cyclopropanamine followed by *Mitsunobu* reaction and acidic deprotection (Scheme 1). To complement our analysis with the detection of putative reversible binders, we synthesized probe **FBPP2** bearing a diazirine photocrosslinker moiety *via* an analogous synthetic strategy (Scheme 1). Prior to proteomic studies with **FBP2**, we determined apparent  $\text{IC}_{50}$  values for MAOA and MAOB using an AzBTS/peroxidase-coupled assay and compared them to tranylcypromine (Fig. S1, ESI<sup>†</sup>). Satisfyingly, the alkyne handle did not strongly affect the inhibition of MAOA ( $\text{IC}_{50} = 0.5 \mu\text{M}$ ) was largely comparable,



**Fig. 2** (A) Schematic depiction of a label-free quantitative proteomic experiment using avidin beads for target protein enrichment. (B) Results of target enrichment experiments using **FBP2** in the human cancer cell line HeLa with 100  $\mu\text{M}$  probe concentration. The scatter plot shows statistical significance of protein enrichment levels over protein enrichment ratios from probe treated to control cells. Cut offs are at a  $p\text{-value} < 0.01$  and 4-fold enrichment (indicated by solid lines). Proteins within these set criteria are highlighted in yellow and described in more detail in the corresponding Table 1. MAOA is highlighted in purple. (C) Result of the corresponding competition experiment using **FBP2** in the human cancer cell line HeLa. The scatter plots show statistical significance of protein enrichment levels over protein enrichment ratios from tranylcypromine treated to control cells.




Table 1 Covalent protein targets of **FBP2** in HeLa cells

No.	Gene name	Enrichment	Significance
		$\log_2(\text{Probe/DMSO})$	$-\log_{10}(p\text{-value})$
1	BST2	5.24	4.72
2	CTSL1	3.78	4.00
3	PNPLA4	3.69	4.00
4	HNRNPDL	3.63	5.03
5	PQBP1	3.14	3.50
6	ALDH2	3.10	6.92
7	ABHD6	3.06	4.79
8	MAOA	2.72	2.72
9	CHMP1B	2.68	3.32
10	ALDH1B1	2.64	5.74
11	C19orf43	2.53	3.57
12	HMOX2	2.51	4.64

whereas a decrease in inhibition of MAOB ( $IC_{50} = 2.3 \mu\text{M}$ ) was observed. As a reference, we also prepared a structurally unrelated probe (**FBP1**) based on the pargyline scaffold as reported previously.<sup>10</sup> This probe was already validated to target MAO enzymes *via* gel-based studies.

With these probes in hand, we turned our attention to the profiling of tranylecypromine in human cell lines. We selected SH-SY5Y due to its widespread use as a model cell line for studying neuronal function and neurodegenerative disorders like Parkinson's disease, as well as HeLa for a complementary approach.<sup>18</sup> First we determined optimal conditions for **FBP2** by concentration dependent gel-based labelling experiments (Fig. S2, ESI<sup>†</sup>). For subsequent target identification and quantification, SH-SY5Y and HeLa cells were treated with either **FBP1** or **FBP2** at 100  $\mu\text{M}$  for 1 h; DMSO treated samples were



**Fig. 3** (A) Results of the photo-affinity labelling experiment in SH-SY5Y cells using **FBP2**. The scatter plot shows statistical significance of protein enrichment levels over protein enrichment ratios from probe treated to control cells. Cut offs are at a  $p$ -value  $< 0.01$  and 4-fold enrichment (indicated by solid lines). Proteins annotated to be located in the lysosomal lumen (GO:0043202) are highlighted in blue. (B) Violin plot demonstrating the significant decrease of lysosomal lumen (LL) protein enrichment when incubating the cells with chloroquine (CQ) prior to **FBP2** treatment ( $****P < 0.0001$ , two-tailed unpaired  $t$ -test). (C) Fluorescence imaging with LAMP1 (green) and **FBP2** clicked to TAMRA-azide (red) in fixed SH-SY5Y cells. The left panel shows strong colocalization (yellow) between lysosomes and probe. The right panel displays release of the probe from lysosomes by pre-treatment of cells with chloroquine (CQ) (scale bar: 5  $\mu\text{m}$ ).



included as control. After lysis, proteins were conjugated to biotin azide using click chemistry. Biotin-labelled target proteins were enriched on avidin beads, and further processed by tryptic digest for quantitative LC-MS/MS analysis and label-free quantification (Fig. 2A). In accordance with previous work, pargyline probe **FBP1** revealed MAOA as the major target with an 81-fold enrichment over DMSO treated SH-SY5Y cells, followed by only one other significantly enriched protein, ALDH1B1, throughout both cell lines (Fig. S3A and B, ESI†).<sup>10</sup> While MAOB was among the top hits in HeLa cells, no enrichment could be observed in SH-SY5Y. In contrast, labelling with the tranlycypromine derived probe **FBP2** resulted in a comparatively low 3.6-fold enrichment of MAOA and no MAOB labelling in both cell lines (Fig. 2B and Fig. S3C, ESI†). Strikingly, multiple off-targets were observed, including ALDHs, heme oxygenase 2 and cathepsin L1 as significantly enriched hits (Fig. 2B, Fig. S3C (ESI†) and Table 1). To further validate these results, we performed a competitive analysis by pre-treating the cells with an excess of unmodified tranlycypromine and pargyline followed by probe incubation. Through this, MAOA and several off-targets including ALDHs and cathepsin L1 could be outcompeted by addition of both parent drugs in either cell line (Fig. 2C and Fig. S4, ESI†). Again, **FBP2** revealed binding to more proteins than **FBP1**, confirming its higher promiscuity throughout the cell lines. With a panel of putative off-targets in hand, we performed initial binding and activity assays to monitor the consequences of tranlycypromine treatment. We obtained recombinant HMOX2 and ALDH2, two representative proteins with importance for cellular functions, and confirmed labelling with the probe (Fig. S5, ESI†). However, we were not able to monitor a reduction of their activity upon compound treatment, suggesting, that at least for these proteins inhibition seems not to be the main consequence of drug binding (data not shown). Nevertheless, it cannot be excluded that alteration of protein pathways by impaired protein-protein interactions contribute to a global cellular dysregulation. This notion was further supported by labelling with the photoprobe **FBPP2**, which enriched even more proteins (Fig. 3A and Fig. S6A, ESI†). Strikingly, competition with tranlycypromine confirmed binding to proteins, e.g. CTSL and ALDH1B1, detected with **FBP2**, yet no additional off-targets were confirmed for the drug (Fig. S6B, ESI†). Interestingly though, when analysing the proteins by cellular compartment, strong prevalence of lysosomal targets was found (Fig. 3A and Fig. S6A, ESI†). This emphasizes that, in line with the primary amino functionality, the compound is trapped in acidic organelles and physically interacts with binding partners in this compartment likely due to spatial proximity.<sup>19</sup>

As the therapeutic MAO targets are located in mitochondria, lysosomal trapping for tranlycypromine lowers the effective dose at the cellular compartment of interest. To explore the possibility of manipulating this effect, we repeated photo-affinity labelling with cells that were either pre-treated with chloroquine or DMSO. Chloroquine has been long marketed for the treatment of malaria, but regained interest in the COVID-19 crisis for its antiviral effect by increasing lysosomal pH.<sup>20</sup> The result of this experiment nicely shows a very significant

decrease of **FBPP2** binding to proteins annotated to be located in the lysosomal lumen (Fig. 3B). As the mean enrichment of all other proteins remains nearly unaltered, it emphasises the strong interaction of tranlycypromine with lysosomal proteins.

To visualize these intriguing findings, we used fluorescence imaging of SH-SY5Y cells treated with **FBP2**. In accordance to our previous results, we saw predominant localization of the probe in the lysosome (as visualized by the specific marker for LAMP1) (Fig. 3C). Most importantly, when pre-treating the cells with lysosomotropic compounds, either chloroquine or tamoxifen, a clear release of the tranlycypromine probe from the lysosomes was detectable (Fig. 3C and Fig. S7, ESI†).

## Conclusions

Due to its unique binding mechanism to monoamine oxidases and use in various diseases, tranlycypromine has been subject to extensive scientific research, yet many aspects of this compound, like side effects or drug-drug-interactions remain hitherto unknown. The aim of this study, was to utilize modern LC-MS/MS technology, in order to find reversible and irreversible protein targets of tranlycypromine. With our novel probe, we were able to show that tranlycypromine, in contrast to pargyline, irreversibly binds to many off-targets. Additionally, by using a photoprobe as well as fluorescence imaging, we proved strong lysosomal trapping of the compound that can be reduced by addition of the lysosomotropic compounds chloroquine and tamoxifen. Co-administration of therapeutic doses of chloroquine and tranlycypromine is known to cause severe side effects and was therefore not investigated further. As our results show a release of tranlycypromine from the lysosome, these findings could become a starting point for new studies, looking into the possible use of lysosomotropic drugs to decrease tranlycypromine dosage.

## Note

MS-data are available *via* ProteomeXchange with identifier PXD018580.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This work was funded by the European Research Council (ERC) and the European Union's Horizon 2020 research and innovation programme (grant agreement no. 725085, CHEMMINE, ERC consolidator grant). We thank K. Bäuml and M. Wolff for technical assistance and I. Hübner, S. Hacker and S. Ruddell for careful proof reading.

## References

- 1 R. McDermott, D. Tingley, J. Cowden, G. Frazzetto and D. D. P. Johnson, Monoamine oxidase A gene (MAOA)



- predicts behavioral aggression following provocation, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**(7), 2118–2123.
- 2 D. Kim, S. H. Baik, S. Kang, S. W. Cho, J. Bae, M.-Y. Cha, M. J. Sailor, I. Mook-Jung and K. H. Ahn, Close Correlation of Monoamine Oxidase Activity with Progress of Alzheimer's Disease in Mice, Observed by in Vivo Two-Photon Imaging, *ACS Cent. Sci.*, 2016, **2**(12), 967–975.
  - 3 M. B. H. Youdim, D. Edmondson and K. F. Tipton, The therapeutic potential of monoamine oxidase inhibitors, *Nat. Rev. Neurosci.*, 2006, **7**(4), 295–309.
  - 4 P. Riederer and G. Laux, MAO-inhibitors in Parkinson's Disease, *Experimental Neurobiology*, 2011, **20**(1), 1–17.
  - 5 S. K. Al-Nuaimi, E. M. Mackenzie and G. B. Baker, Monoamine oxidase inhibitors and neuroprotection: a review, *Am. J. Ther.*, 2012, **19**(6), 436–448.
  - 6 R. Shi, Q. Wu, C. Xin, H. Yu, K.-L. Lim, X. Li, Z. Shi, C.-W. Zhang, L. Qian, L. Li and W. Huang, Structure-Based Specific Detection and Inhibition of Monoamine Oxidases and Their Applications in Central Nervous System Diseases, *ChemBiochem*, 2019, **20**(12), 1487–1497.
  - 7 J. Huang, F. Liu, H. Tang, H. Wu, L. Li, R. Wu, J. Zhao, Y. Wu, Z. Liu and J. Chen, Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model, *Front. Neurol.*, 2017, **8**, 626.
  - 8 E. Spina and M. G. Scordo, Clinically significant drug interactions with antidepressants in the elderly, *Drugs Aging*, 2002, **19**(4), 299–320.
  - 9 S. Bleakley, Antidepressant drug interactions: evidence and clinical significance, *Prog. Neurol. Psychiatry*, 2016, **20**(3), 21–27.
  - 10 J. M. Krysiak, J. Kreuzer, P. Macheroux, A. Hermetter, S. A. Sieber and R. Breinbauer, Activity-based probes for studying the activity of flavin-dependent oxidases and for the protein target profiling of monoamine oxidase inhibitors, *Angew. Chem., Int. Ed.*, 2012, **51**(28), 7035–7040.
  - 11 L. Li, C.-W. Zhang, J. Ge, L. Qian, B.-H. Chai, Q. Zhu, J.-S. Lee, K.-L. Lim and S. Q. Yao, A Small-Molecule Probe for Selective Profiling and Imaging of Monoamine Oxidase B Activities in Models of Parkinson's Disease, *Angew. Chem., Int. Ed.*, 2015, **54**(37), 10821–10825.
  - 12 H. Fang, H. Zhang, L. Li, Y. Ni, R. Shi, Z. Li, X. Yang, B. Ma, C. Zhang, Q. Wu, C. Yu, N. Yang, S. Q. Yao and W. Huang, Rational Design of a Two-Photon Fluorogenic Probe for Visualizing Monoamine Oxidase A Activity in Human Glioma Tissues, *Angew. Chem., Int. Ed.*, 2020, **59**, 7536.
  - 13 X. Wu, W. Shi, X. Li and H. Ma, A Strategy for Specific Fluorescence Imaging of Monoamine Oxidase A in Living Cells, *Angew. Chem., Int. Ed.*, 2017, **56**(48), 15319–15323.
  - 14 X. Wu, L. Li, W. Shi, Q. Gong, X. Li and H. Ma, Sensitive and Selective Ratiometric Fluorescence Probes for Detection of Intracellular Endogenous Monoamine Oxidase A, *Anal. Chem.*, 2016, **88**(2), 1440–1446.
  - 15 Z. Yang, W. Li, H. Chen, Q. Mo, J. Li, S. Zhao, C. Hou, J. Qin and G. Su, Inhibitor structure-guided design and synthesis of near-infrared fluorescent probes for monoamine oxidase A (MAO-A) and its application in living cells and *in vivo*, *Chem. Commun.*, 2019, **55**(17), 2477–2480.
  - 16 C. Binda, M. Li, F. Hubalek, N. Restelli, D. E. Edmondson and A. Mattevi, Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**(17), 9750–9755.
  - 17 K. L. Kirk, S. Yoshida and G. Haufe, Synthesis and Biochemical Evaluation of Fluorinated Monoamine Oxidase Inhibitors, *Fluorine Health*, 2008, 661–697.
  - 18 H. Xicoy, B. Wieringa and G. J. M. Martens, The SH-SY5Y cell line in Parkinson's disease research: a systematic review, *Mol. Neurodegener.*, 2017, **12**(1), 10.
  - 19 A. M. Zuhl, C. E. Nolan, M. A. Brodney, S. Niessen, K. Atchison, C. Houle, D. A. Karanian, C. Ambroise, J. W. Brulet, E. M. Beck, S. D. Doran, B. T. O'Neill, C. W. Ende, C. Chang, K. F. Geoghegan, G. M. West, J. C. Judkins, X. Hou, D. R. Riddell and D. S. Johnson, Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of  $\beta$ -secretase inhibitors, *Nat. Commun.*, 2016, **7**, 13042.
  - 20 S. Lu, T. Sung, N. Lin, R. T. Abraham and B. A. Jessen, Lysosomal adaptation: how cells respond to lysosomotropic compounds, *PLoS One*, 2017, **12**(3), e0173771.

